newsfilter
← Latest News
GlobeNewswire·

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 CongressData supplements unprecedented two-year data from the trial including a 75% Objective Response